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Human La protein is known to interact with hepatitis C virus (HCV) internal ribosome entry site (IRES) and
stimulate translation. Previously, we demonstrated that mutations within HCV SL IV lead to reduced binding
to La-RNA recognition motif 2 (RRM2) and drastically affect HCV IRES-mediated translation. Also, the
binding of La protein to SL IV of HCV IRES was shown to impart conformational alterations within the RNA
so as to facilitate the formation of functional initiation complex. Here, we report that a synthetic peptide,
LaR2C, derived from the C terminus of La-RRM2 competes with the binding of cellular La protein to the HCV
IRES and acts as a dominant negative inhibitor of internal initiation of translation of HCV RNA. The peptide
binds to the HCV IRES and inhibits the functional initiation complex formation. An Huh7 cell line constitu-
tively expressing a bicistronic RNA in which both cap-dependent and HCV IRES-mediated translation can be
easily assayed has been developed. The addition of purified TAT-LaR2C recombinant polypeptide that allows
direct delivery of the peptide into the cells showed reduced expression of HCV IRES activity in this cell line.
The study reveals valuable insights into the role of La protein in ribosome assembly at the HCV IRES and also
provides the basis for targeting ribosome-HCV IRES interaction to design potent antiviral therapy.
Hepatitis C virus (HCV), a member of the Flaviviridae family,
is an enveloped positive-sense, single-stranded RNA virus (10).
The 9.6-kb-long genome encodes a single polyprotein of about
3,000 amino acids. The polyprotein is processed by host cell
and viral proteases into three major structural proteins and
several nonstructural proteins necessary for viral replication (4,
18). HCV causes a variety of liver diseases in humans, includ-
ing liver cirrhosis and hepatocellular carcinoma (20, 32). It is
estimated that about 3% of the world population is infected
with HCV, and about 85% of infected individuals develop
chronic infection. Current options for treating HCV involve
alpha interferon alone or in combination with ribavirin (6, 13).
However, these treatments fail to achieve sustained virological
response in the majority of patients, thus emphasizing the need
for novel therapeutic approaches to combat HCV infection.
Translation initiation of HCV occurs in a cap-independent
manner wherein the ribosomes are recruited onto an internal
ribosome entry site (IRES) located mostly within the 5 un-
translated region (UTR) and extending a few nucleotides into
the coding region (31, 37, 39). HCV IRES has been shown to
form three complex stem-loops and a pseudoknot, which en-
compasses the initiator AUG codon (7). Although the HCV
IRES binds to the 40S ribosomal subunit specifically and stably
even in absence of any initiation factors, efficient translation
requires canonical initiation factors like eIF2 and eIF3 (21, 27,
33) and other noncanonical trans-acting cellular proteins in-
cluding polypyrimidine tract-binding protein (1), La autoanti-
gen (2), poly(rC) binding protein (15), and heterogeneous nu-
clear ribonucleoprotein L (p68) (19). Recently, binding of a
25-kDa cellular protein (p25) to HCV IRES has been shown to
be important for efficient translation initiation. p25 was origi-
nally suggested to be ribosomal protein S9 but was later iden-
tified as rpS5 (14, 16, 27).
Human La protein is known to interact with HCV IRES and
stimulate translation initiation both in vitro and in vivo (2, 3).
La protein has been shown to specifically interact with both the
5 and 3 UTRs of hepatitis C virus RNA (34). Sequestration
of La in rabbit reticulocyte lysate (RRL) inhibits HCV IRES-
mediated translation, which can be rescued by exogenous ad-
dition of purified La protein (3). However, it has been noted
that HCV IRES has a lower requirement of La protein than
poliovirus (PV) IRES (22). Due to the critical role played by
the La protein in HCV IRES translation, the disruption of its
interaction with HCV IRES is an attractive target for inhibit-
ing HCV IRES activity. A 60-nucleotide inhibitor RNA (I-
RNA) from the yeast Saccharomyces cerevisiae that preferen-
tially blocked HCV and poliovirus IRES-mediated translation
appeared to inhibit the translation by virtue of its ability to bind
La protein (12). Recently, it has been shown that a synthetic
peptide corresponding to the N-terminal “La motif” of human La
autoantigen inhibits HCV IRES-mediated translation possibly by
binding to other essential cellular proteins (23).
La protein has been shown to have three putative RNA
recognition motifs (RRMs) and a basic region followed by a
stretch of acidic region at the C terminus (17). We previously
demonstrated that both N- and C-terminal halves of La protein
are able to interact with HCV IRES and were able to stimulate
HCV IRES-mediated translation, unlike the case in poliovirus
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IRES, suggesting that the deletion of the C terminus does not
abrogate the ability of La protein to enhance the translation of
hepatitis C virus. Among the three RRMs, RRM2 showed the
highest affinity for binding to HCV IRES RNA. Additionally,
using comparative sequence and structural analysis as well as
primer extension inhibition analysis, we demonstrated previ-
ously that the RRM2 within the N-terminal domain of La
protein binds HCV RNA at the GCAC motif near the initiator
AUG (28). Recent reports from our laboratory also high-
lighted the fact that mutations within HCV SL IV lead to
reduced binding to La-RRM2 and drastically affect HCV
IRES-mediated translation. Also, the binding of La protein to
SL IV of HCV IRES was shown to impart conformational
alterations within the RNA so as to facilitate the formation of
a functional initiation complex (29). Similarly, another recent
report suggests direct involvement of La protein in the initia-
tion of formation of 48S ribosome complexes on HCV IRES
RNA (11).
Here, we studied the role of La protein in assisting the
assembly of a translation initiation complex by using a domi-
nant negative synthetic peptide, LaR2C, derived from the C
terminus of La-RRM2. The peptide retained the RNA binding
ability and successfully competed with cellular La protein for
binding to the SL IV region of the HCV IRES RNA. More
importantly, it appears that the LaR2C peptide interferes with
the assembly of 48S complexes, resulting in the accumulation
of preinitiation complexes that are incompetent for the 60S
ribosomal subunit joining. The results reinforce the role of La
protein in the formation of the functional initiation complex on
the HCV IRES RNA (11, 29). Finally, the peptide has been
successfully exploited as a dominant negative inhibitor of HCV
IRES-mediated translation. The LaR2C sequences expressed
as a fusion to HIV-TAT peptide, when introduced into the
Huh7 cell line constitutively expressing the HCV bicistronic
construct, significantly reduced the HCV IRES-mediated
translation. The study put forward the idea of targeting ribo-
some-IRES interaction to design potent antiviral therapeutics
against HCV infection.
MATERIALS AND METHODS
Plasmids, peptides, and cells. The plasmids pRSET A-La, pRSET A-La101-
208 (RRM2), pcD HCV-383 bicistronic construct, pcD HCV-383 WT and pcD
HCV-383 M2, and pHCV-383 GFP have been described previously (28, 29). The
PV 5 UTR was cloned in between HindIII and EcoRI sites replacing HCV
IRES in the bicistronic plasmid (30), and the pFLuc-HAV-GFP bicistronic
construct was cloned as described previously (38). pcDGFP was obtained by
inserting green fluorescent protein (GFP) into EcoRI/XhoI of the pcDNA3
vector. La101-180 and La120-208 coding sequences were PCR amplified using
the primers 5-GGCCGGATCCGAAGTGACTTGGGA-3, 5-GGCTGAATT
CCAGGTCTGTTTCTTT-3, 5-GCATGGATCCACTGATGCAACTCTT-3,
and 5-CGTAGAATTCCTACTGGTCCCAG-3 and pRSET A-La as template
DNA. The amplified products were cloned into BamHI and EcoRI sites of the
vector pRSET A to obtain pRSET A-La101-180 and pRSET A-La120-208.
pTAT and pTAT-HA vectors were obtained from S. Vijaya of our department
with permission from Steven F. Dowdy, Howard Hughes Medical Institute,
Washington University School of Medicine. The La174-197 coding sequence was
amplified using the primers 5-CGCGCTCGAGAAGTACAAAGAAACA-3
and 5-CCGGGAATTCTTTTCTTTCTTCATT-3, from the template pRSET
A-La, and cloned into XhoI and EcoRI sites of the pTAT vector to obtain
pTAT-LaR2C. The PCRs were carried out with 30 cycles, each cycle consisting
of a denaturation step (95°C for 40 s), an annealing step (55°C for 1 min), and
an extension step (68°C for 1 min/1 kb) using Pfx DNA polymerase (Invitrogen).
The peptide LaR2C (corresponding to residues 174 to 197 of the La protein),
containing the sequence KYKETDLLILFKDDYFAKKNEERK, was custom
synthesized at Sigma Genosys, with a final purity of 90%. The nonspecific peptide
(NSP)-La contains the sequence ALSKSKAELMEISEDKTK (Sigma), which
was used as a negative control previously in a similar study reported by the
laboratory of Asim Dasgupta, School of Medicine, University of California—Los
Angeles, Los Angeles, Calif. (23). The NSP containing the sequence RVKQIT
NSPGKKTMPGVKLSPGKVTT (Sigma) was kindly provided by Raghavan
Varadarajan, Molecular Biophysics Unit, Indian Institute of Science. The pep-
tides were dissolved in nuclease/protease-free water, and the integrity was
checked by gel electrophoresis followed by silver staining.
HeLa and Huh7 cells were maintained as monolayers in Dulbecco’s modified
Eagle’s medium (MEM) containing 10% fetal bovine serum. Huh7 cells grown in
30-mm dishes at 60 to 70% confluence were transfected with 2 g of the pcD
HCV-383 bicistronic construct using Tfx 20 transfection reagent (Promega)
according to the manufacturer’s protocol. Briefly, the DNA was mixed with 5 l
of Tfx 20 reagent and diluted to 1 ml using MEM (Invitrogen) and incubated at
room temperature for 15 min. The cells were washed with medium and overlaid
with 1 ml of MEM containing the above-described DNAs. After 1 hour of
incubation at 37°C, 0.8 ml of MEM and 0.2 ml of fetal bovine serum (Invitrogen)
was added to the dishes. The transfected cells were selected by adding antibiotic
G418 to the dishes to a final concentration of 1.2 mg/ml. The Huh7/HCV-bicis
cells were then maintained in medium containing 500 g/ml G418. The antibi-
otic-resistant cells were harvested and further selected by dilutional cloning.
Purification of La full-length and truncated proteins using Ni-NTA agarose
column. Escherichia coli BL21(DE3) cells were transformed with pRSET-A
vectors containing either the full-length or the deletion mutants of RRM2. Single
colonies were inoculated into 5 ml of LB broth containing 75 g/ml ampicillin
and grown at 37°C with an incubator shaker at 200 rpm until the optical density
at 660 nm reached 0.6. The cultures were induced with 0.6 mM IPTG (isopropyl-
-D-thiogalactopyranoside) and grown for a further 4 h. The cells were pelleted
and resuspended in 200 l lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM
imidazole). The extract was made by sonication. The above-described crude
extracts were mixed with a one-quarter volume of Ni-nitrilotriacetic acid (NTA)
agarose slurry (QIAGEN) and kept with rocking at 4°C for 2 h. The lysate was
loaded onto a column, and the flowthrough was discarded. The column was
washed with 5 ml of wash buffer (50 mM NaH2PO4, 300 mM NaCl, 40 mM
imidazole). The bound protein was eluted with 500 l of elution buffer contain-
ing 500 mM imidazole. The eluted proteins were dialyzed at 4°C for 4 to 6 h in
500 ml dialysis buffer (50 mM Tris, pH 7.4, 100 mM KCl, 7 mM -mercapto-
ethanol, 20% glycerol), aliquoted, and stored in a freezer at70°C. TAT-LaR2C
and TAT-hemagglutinin (HA) proteins were purified under denaturing condi-
tions as described previously (5) after transforming pTAT-LaR2C and
pTAT-HA vectors into BL21 cells. The purified proteins were refolded by step
dialysis against dialysis buffer (20 mM HEPES, 100 mM NaCl, and 10% glycerol)
containing decreasing concentration (6, 4, 2, and 0 M) of urea. Purity of all the
purified proteins was verified by gel electrophoresis followed by silver staining.
Preparation of HeLa S10 cell extract. HeLa S10 cell extract was prepared as
described previously (29). Briefly, cells were harvested, pelleted down, and
washed three times with cold isotonic buffer (35 mM HEPES, pH 7.4, 146 mM
NaCl, 11 mM glucose), resuspended in a 1.5 packed cell volume of hypotonic
buffer (10 mM HEPES, pH 7.4, 15 mM KCl, 1.5 mM Mg-acetate, and 6 mM
-mercaptoethanol), and then incubated on ice for 10 min. Cells were then
transferred to a Down’s homogenizer and disrupted by 50 strokes on ice (lysis
was checked under a microscope). The lysate was incubated in 1 incubation
buffer for 10 min. S10 cytoplasmic extract was isolated by centrifuging the lysate
at 10,000  g for 30 min at 4°C. The supernatant was dialyzed for 4 h against 100
volumes of dialysis buffer and aliquoted into prechilled tubes. The aliquots of S10
extract were stored at 70°C.
In vitro transcription mRNAs were transcribed in vitro from different linear-
ized plasmid constructs under T7 promoters in runoff transcription reactions.
The monocistronic construct pcD GFP was linearized with XhoI downstream of
GFP to be used as templates for RNA synthesis. The linear DNAs were elec-
trophoresed on agarose gels and extracted by using a QIAGEN gel elution kit,
and capped bicistronic RNAs were synthesized using a Ribomax large-scale
RNA production system-T7 (Promega) under standard conditions with the ad-
dition of 5 cap analog (Promega). For the synthesis of uncapped HCV-GFP
RNA, pcD HCV-383 GFP linearized with XhoI was used, and for the synthesis
of HCV wild-type and mutant IRES RNAs, pcD HCV-383 WT or pcD HCV-383
M2 (29) linearized with EcoRI downstream of HCV IRES was used. The tran-
scription was performed using Ribomax large-scale RNA production system-T7
(Promega) according to the manufacturer’s protocol.
Radiolabeled mRNAs were transcribed in vitro using T7 RNA polymerase
(Promega) and [-32P]UTP (NEN). pcD HCV-383 was linearized with EcoRI,
gel eluted, and transcribed in vitro to generate the 32P-labeled RNA. The tran-
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scription reaction was carried out under standard conditions (Promega protocol)
using 2.5 g of linear template DNA at 37°C for 1 h 30 min. After alcohol
precipitation, the RNA was resuspended in 25 l of nuclease-free water. One
microliter of the radiolabeled RNA sample was spotted onto DE81 filter paper,
washed with phosphate buffer, and dried, and the incorporated radioactivity was
measured using a liquid scintillation counter.
Filter-binding assay. The 32P-labeled HCV 383 RNA was incubated with
increasing concentrations of purified recombinant proteins or peptides at 30°C
for 15 min in RNA binding buffer (containing 5 mM HEPES, pH 7.6, 25 mM
KCl, 2 mM MgCl2, 3.8% glycerol, 2 mM dithiothreitol, and 0.1 mM EDTA), and
loaded onto nitrocellulose filters equilibrated with the 2 ml RNA binding buffer.
The filters were then washed twice with 2 ml of binding buffer and dried, and the
counts retained were measured with a liquid scintillation counter. The graph was
plotted with protein concentration (nanomolars) on the x axis and the percentage
of bound RNA as the percentage of counts retained on the y axis. Each exper-
iment was repeated three times, and the representative experiments are shown in
the figures.
In vitro translation. In vitro translation of the capped or uncapped monocis-
tronic mRNAs was carried out in micrococcal nuclease-treated RRL (Promega
Corporation, WI). Briefly, 25-l reaction mixtures contained 1 g template
RNA, 17.5 l of RRL containing 0.5 l of minus methionine, 20 Ci [35S]me-
thionine, and 10 units of RNasin (Promega). The reaction mixtures were incu-
bated at 30°C for 1 h 30 min. The expression from capped GFP or uncapped
HCV-GFP RNAs in monocistronic constructs was resolved on a 12% sodium
dodecyl sulfate (SDS)-polyacrylamide gel and dried before analysis using a Phos-
phorImager.
Primer extension inhibition analysis. Primer extension inhibition (toe-print-
ing) assay was performed as described previously (21). Briefly, increasing con-
centrations of the peptides LaR2C and NSP were incubated with 5 pmol of in
vitro-transcribed RNA corresponding to the HCV IRES (residues 18 to 383),
and binding reaction was performed in a final volume of 20 l at 30°C for 20 min.
To this reaction, 32P-end-labeled primer complementary to 25 nucleotides of the
3 end of the HCV-383 was added and allowed to extend using 3 units of
AMV-Reverse Transcriptase (Promega) at 30°C for 1 hour. The cDNAs were
alcohol precipitated, resuspended, and compared with the dideoxynucleotide
sequence ladders by electrophoresis on a 6% polyacrylamide–7 M urea denatur-
ing gel.
UV cross-linking assay. Radiolabeled RNA corresponding to the HCV IRES
was allowed to form a complex with the purified recombinant La protein, cell
extract, or synthetic peptides in binding buffer (5 mM HEPES [pH 7.6], 25 mM
KCl, 2 mM MgCl2, 3.8% glycerol, 2 mM dithiothreitol, 0.1 mM EDTA) at 30°C
for 15 min. These RNA-protein complexes were then irradiated with short-
wavelength UV light for 15 min. The excess and unbound RNA was digested with
30 g of RNase A (Sigma) for 30 min at 37°C. The proteins were then denatured
in 1 SDS buffer and resolved on an SDS-polyacrylamide gel, which was dried
before it was exposed to the PhosphorImager. For competition experiments, the
labeled RNA was preincubated with the peptides for 10 min before adding the
La wild type or cell extracts.
Transduction of TAT-LaR2C into Huh7/HCV-bicis cells. Huh7/HCV-bicis
cells were grown to 60 to 70% confluency in 30-mm dishes. After medium was
removed, the cells were washed with fresh medium, and then the proteins
TAT-LaR2C and TAT-HA were added to the medium to a final concentration
of 100 nM. Proteins were incubated on the cells for 10 min at 37°C and then
washed twice with phosphate-buffered saline. The cells were then harvested at
different time intervals in 200 l of 1 passive lysis buffer. Ten microliters of cell
extract was used to measure Renilla luciferase (RLuc) and firefly luciferase
(FLuc) reporter gene activities using the Dual Luciferase assay system (Pro-
mega) according to the manufacturer’s protocol. The transfection experiment
data are expressed as means  standard deviations of three independent repli-
cates.
Sucrose gradient centrifugation analysis of ribosomal assembly on HCV
IRES. The ribosome assembly analysis experiment was performed as described
previously (29). Briefly, 32P-radiolabeled HCV IRES RNA (	2  105 cpm) was
added to 25 l of ribosome assembly reaction mixtures in the presence or
absence of the La peptide (LaR2C) or 10 mM 5-guanylyl-imidophosphate
(GMP-PNP; Sigma-Aldrich). The reaction mixtures were diluted to 150 l with
gradient buffer (20 mM Tris [pH 7.5], 100 mM KCl, 3 mM MgCl2, 1 mM
dithiothreitol) and overlaid on a 5 to 30% (wt/vol) linear sucrose gradient. The
ribosomal complexes were sedimented by ultracentrifugation for 3 hours at 4°C
and 30,000 rpm using a Beckman SW41 swing bucket rotor. Fractions (200 l)
were manually collected from the bottom of the tube, and the radioactivity was
counted with a Rackbeta liquid scintillation counter. Each experiment was re-
peated three times, and the representative experiments are shown in the figures.
RESULTS
RRM2 of La protein binds to HCV IRES through its C-
terminal residues. Previously, we have shown that RRM2 of
La protein binds to HCV IRES with high affinity. To precisely
identify the region that is important for the binding, two de-
letion constructs of La-RRM2 (La101-180 and La120-208)
with deletions of 20 amino acids from the N terminus and 28
amino acids from the C-terminal region were generated (Fig.
1A). The overexpressed and purified proteins were analyzed by
gel electrophoresis followed by silver staining (Fig. 1B) and
used to study their ability to bind HCV IRES RNA using the
filter-binding assay. 32P-labeled HCV IRES RNA was incu-
bated with increasing concentrations of La-RRM2 (La101-
208), La101-180, or La120-208 proteins in RNA-binding
buffer. The RNA-protein complexes were bound to nitrocellu-
lose filters and washed with binding buffer to remove unbound
RNA. The counts retained were plotted against the protein
concentration to obtain a saturation curve. The results showed
that La120-208 retained the ability to bind HCV IRES RNA
with an affinity of 0.16 M, which was comparable to the
affinity of La-RRM2 (0.14 M), while the RNA binding ability
was drastically affected in La101-180, where the C-terminal 28
amino acids were deleted (Fig. 1C). The results indicated that
the C-terminal amino acids of La-RRM2 contribute to the
binding with HCV IRES RNA.
Peptide LaR2C, derived from the C terminus of La-RRM2,
is capable of binding to HCV IRES RNA. Based on the filter-
binding assay results with La101-180 and La120-208 and the
information obtained from the computational modeling (28), a
synthetic peptide (LaR2C) of 24 amino acids (La174-197),
corresponding to the C terminus of La-RRM2, was custom
synthesized and tested for its ability to bind to HCV IRES
using a filter-binding assay. A nonspecific peptide of similar
length was used as a negative control. Additionally, another
peptide (NSP-La), corresponding to the sequences closer to
the N-terminal region of La protein (amino acids 71 to 88),
which has been used previously as a nonspecific control in a
similar study (23), was used as a negative control. The integ-
rities of the La peptide (LaR2C), NSP-La, and NSP were
checked by gel electrophoresis followed by silver staining (Fig.
2A). The filter-binding results showed that LaR2C retained the
ability to bind to HCV IRES with an affinity of 75 M, al-
though the affinity was much lower than that of La protein
(0.12 M). The nonspecific peptides NSP and NSP-La did not
show any binding to the RNA (Fig. 2B). Since both of the
nonspecific peptides failed to bind HCV IRES RNA, we de-
cided to carry out the rest of the experiments with the NSP as
a negative control, which is of similar length to that of LaR2C
peptide. To further confirm the LaR2C binding with HCV
IRES RNA, a UV cross-linking assay was used where increas-
ing concentrations of LaR2C or NSP were used to bind to
32P-labeled HCV IRES RNA. After the removal of unbound
RNA by RNase A treatment, the protein-nucleotidyl com-
plexes were subjected to SDS–15% polyacrylamide gel electro-
phoresis (PAGE) followed by phosphorimaging analysis.
LaR2C showed efficient binding to HCV IRES RNA in a
dosage-dependent manner (Fig. 2C, lanes 2 to 4), while the
NSP of similar length did not show any binding (Fig. 2C, lanes
5 to 7). To study the specificity of the interaction further, a
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competition UV cross-linking assay was performed where the
binding of LaR2C with 32P-labeled HCV IRES was competed
with 100- and 200-fold molar excesses of unlabeled HCV IRES
RNA (self-RNA). The results showed that the unlabeled HCV
wild-type IRES RNA efficiently competed out the binding
(Fig. 2D, lanes 3 to 4), confirming the specificity of the inter-
action of LaR2C with HCV IRES RNA.
Previously, we have shown that La-RRM2 binds to HCV
IRES around GCAC near the initiator AUG located in the
stem-loop IV region, and the substitution mutations in SL IV
affect the binding of La-RRM2 to HCV IRES drastically (29).
Since LaR2C encompasses the RNA binding domain of RRM2
and has the ability to bind to HCV IRES, we wanted to verify
if LaR2C binds to HCV IRES at the same region where RRM2
binds. For this purpose, unlabeled HCV mutant IRES RNA
M2, where GCAC residues in SL IV have been substituted
with ACCG (29), was used in the competition UV cross-linking
assay. Even a 100- to 200-fold excess of M2 RNA failed to
compete significantly with the 32P-labeled HCV IRES RNA
for binding to LaR2C (Fig. 2D, lanes 5 to 6). The results clearly
indicated that LaR2C specifically binds to HCV IRES RNA
and perhaps at the same site within the SL IV region where
La-RRM2 has been shown to interact.
LaR2C binds to HCV IRES in the SL IV region near iAUG.
To further confirm the region on HCV IRES RNA where
LaR2C binds, we performed a primer extension-inhibition as-
say (toe printing) using HCV IRES RNA in the absence or
presence of increasing concentrations of the peptide LaR2C.
Increasing concentrations of LaR2C or the NSP were incu-
bated with 5 pmol of in vitro-transcribed HCV IRES RNA. To
this complex, 32P-end-labeled primer complementary to the 3
end of the HCV-383 was added and extended using AMV-
Reverse Transcriptase. The resulting extended products were
analyzed on a 6% polyacrylamide–7 M urea denaturing gel.
For precise mapping of the contact points, a DNA sequencing
reaction corresponding to the HCV 383 RNA and using the
same end-labeled primer was electrophoresed alongside. The
results demonstrated specific reverse transcriptase pauses (toe
prints) with the addition of increasing concentrations of
LaR2C (Fig. 3), indicating possible binding sites. Two specific
toe prints corresponding to C334 and A342 were observed
around the initiator AUG (iAUG) in the SL IV region, which
showed an increase in band intensity with the addition of
increasing concentrations of LaR2C (Fig. 3, compare lane 5
with lanes 6 and 7). The relative band intensities were quan-
FIG. 1. Effect of deletions on the binding of La-RRM2 to HCV IRES RNA. (A) Schematic representation of N- and C-terminal deletions
within La-RRM2. The corresponding amino acid numbers of the truncated proteins are indicated. (B) The purified protein samples (as indicated
on top of the lanes) were analyzed by SDS–10% Tris-Tricine gel followed by silver staining. (C) Filter-binding assay to study the binding of
La101-208, La101-180, and La120-208 to HCV IRES. 32P-labeled HCV IRES RNA was bound to increasing concentrations of La RRM2 or
truncated proteins (as indicated by the symbols within the panel). The amount of bound RNA was determined by binding to the nitrocellulose
filters. The percentage of bound RNA was plotted against the protein concentration (nanomolars).
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titated by densitometry and analyzed for the severalfold in-
crease with respect to the no-protein control (data not shown).
However, no significant increase in toe prints was observed
when a similar concentration of NSP was used (Fig. 3, compare
lane 9 with lane 8). Similar toe prints were observed around
this region when purified full-length La or RRM2 was added in
the reaction (reference 28 and data not shown). The results
indicate that the LaR2C peptide might interact with the SL IV
region of HCV IRES RNA around the iAUG.
LaR2C competes with binding of full-length La protein to
the HCV IRES RNA. We have shown previously that RRM2 of
human La protein binds to the HCV IRES RNA near the
initiator AUG (29). Since we observed that LaR2C also binds
to the SL IV region of the HCV IRES RNA near the initiator
AUG in the present study, we were interested to investigate
whether LaR2C can compete with the full-length protein for
binding to the HCV IRES RNA and, if so, what could be the
possible consequences. To address this, a competition UV
cross-linking experiment was performed with purified recom-
binant La protein and 32P-labeled HCV IRES RNA in the
absence or presence of increasing concentrations of LaR2C
peptide or NSP. The results showed that the binding of La
protein to HCV IRES RNA was partially competed out (up to
40%) with the addition of 20 M and 40 M of LaR2C peptide
FIG. 2. Ability of the peptide LaR2C to bind to HCV IRES RNA. (A) The sequences of the peptides LaR2C, NSP, and NSP-La are indicated.
The LaR2C, NSP, and NSP-La peptides were analyzed by resolving by SDS–12% Tris-Tricine gel electrophoresis followed by silver staining.
(B) Filter-binding assay to study the binding of the peptide LaR2C to HCV IRES. 32P-labeled HCV IRES RNA was bound to increasing
concentrations of the peptide LaR2C, NSP, or NSP-La (as indicated by the symbols within the panel). The amount of bound RNA was determined
by binding to the nitrocellulose filters. The percentage of bound RNA was plotted against the peptide concentration (micromolars). (C) UV
cross-linking of LaR2C and NSP to HCV IRES. 32P-labeled HCV IRES RNA was UV cross-linked with increasing concentrations (20, 40, and
60 M) of either LaR2C or NSP (as indicated above the panel), digested with RNase A, and resolved by SDS–15% PAGE followed by
phosphorimaging. Lane 1 represents the no-protein control. Lane M represents the 14C protein molecular weight marker. The corresponding
molecular masses are indicated to the left of the panel. (D) Competition assay to determine specificity of the binding of LaR2C to HCV IRES
RNA. LaR2C preincubated with 100- and 200-fold excesses of unlabeled HCV wild-type (wt) RNA or HCV M2 RNA (where the SL IV region
was mutated), as indicated above the lanes, was bound to 32P-labeled HCV IRES RNA and UV cross-linked. The complexes were treated with
RNase A and resolved by SDS–15% PAGE followed by phosphorimaging. The band corresponding to LaR2C is indicated to the right of the panels
by arrows. Lane 1 represents the no-protein control. Lane M represents the 14C protein molecular weight marker. The corresponding molecular
masses are indicated to the left of the panel.
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in the binding reaction (Fig. 4, lanes 3 and 4). At a further high
concentration of the peptide (60 M), the competition was
much more pronounced (up to 70%) (Fig. 4A, lane 5). How-
ever, the NSP did not show a similar effect (Fig. 4A, lanes 6 to
8). The result is consistent with the observation that the pep-
tide LaR2C encompassing the region of the full-length La
protein contributed significantly to its binding to HCV IRES
RNA, and when added in trans, this region can significantly
compete with La protein binding to HCV IRES RNA.
To further verify whether LaR2C peptide can compete with
full-length La protein in the context of cytoplasmic extract, a
UV cross-linking experiment was performed using 32P-labeled
HCV IRES RNA and HeLa cell extract in the absence or
presence of increasing concentrations of LaR2C. The results
demonstrated that in the presence of increasing concentrations
of LaR2C, the binding of a 52-kDa polypeptide to the 32P-
labeled HCV IRES RNA was found to be drastically reduced
(Fig. 4B, lanes 2 to 4). Immunoprecipitation of the UV cross-
linked nucleoprotein complex using anti-La antibody showed a
FIG. 3. Primer extension inhibition (toe-printing) analysis. Increas-
ing concentrations of the LaR2C peptide (20 and 40 M [lanes 6 and
7]) or 40 M NSP (lane 9) was incubated with HCV IRES RNA (18
to 383 nucleotides) as described above and analyzed for the toe prints.
Lanes 5 and 8 represent the no-protein control. Lanes 1 to 4 show the
DNA sequencing ladder corresponding to the HCV RNA (18 to 383
nucleotides) obtained by using the same end-labeled primer. The nu-
cleotide indicated on the right of the panel signifies the corresponding
positions on the HCV IRES RNA. The nucleotide positions corre-
sponding to GCAC and iAUG are indicated on the left.
FIG. 4. Effect of LaR2C on the binding of recombinant La protein
and other cellular proteins to HCV IRES RNA. (A) 32P-labeled HCV
IRES RNA was preincubated with increasing concentrations (20, 40,
and 60 M) of LaR2C or NSP as indicated above the lanes and then
bound to recombinant purified La protein. The UV cross-linked com-
plexes were treated with RNase A and resolved by SDS–10% PAGE
followed by phosphorimaging. The band corresponding to recombi-
nant La (rLa) is indicated to the right of the panel. Lane M represents
the 14C-protein molecular weight marker. The corresponding molec-
ular masses are indicated to the left of the panel. The intensity of the
band corresponding to La protein in each lane was quantitated using
densitometry and represented in numbers below the lanes. (B) 32P-
labeled HCV IRES RNA was preincubated with increasing concen-
trations (20, 40, and 60 M) of LaR2C and then bound to HeLa
cytoplasmic extract (2.5 g). The UV cross-linked RNA-protein com-
plexes were treated with RNase A and resolved by SDS–5 to 15%
gradient PAGE followed by phosphorimaging. The band correspond-
ing to p52 is indicated to the right of the panel. The protein bands
whose intensities were reduced are indicated by asterisks. The intensity
of the band corresponding to p52 in each lane was quantitated using
densitometry and represented in numbers below the respective lanes.
Lane M represents the 14C-protein molecular weight marker. The
corresponding molecular masses are indicated to the left of the panel.
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52-kDa cross-linked band from HeLa cell extract correspond-
ing in size to the 52-kDa protein band observed in the above-
described UV cross-linking experiment (data not shown). Re-
sults suggest that the 52-kDa cross-linked band, which showed
decreased binding with HCV IRES upon addition of the
LaR2C peptide, is indeed the La protein. Interestingly, in the
presence of LaR2C peptide, significant changes in band inten-
sities were observed in the binding of some other cellular
proteins to HCV IRES RNA (as indicated with asterisks in Fig.
4). The sizes of some of them were found to be similar to that
of eIF3 subunits (p170 and p66) that were reported to interact
with the HCV IRES RNA. From the above-mentioned obser-
vation, it appears that the LaR2C peptide can compete with
the full-length La protein for binding to the HCV IRES RNA
even in presence of other trans-acting factors in the HeLa
cytoplasmic extract.
LaR2C inhibits HCV IRES-mediated translation in vitro.
Human La autoantigen has been shown to enhance HCV
IRES-mediated translation. Since the RNA-protein interac-
tion studies revealed that the peptide LaR2C binds to HCV
IRES near iAUG and competes with the binding of full-length
La protein to HCV RNA, it was interesting to study whether
LaR2C has any effect on HCV IRES-mediated translation. For
this purpose, monocistronic RNA, HCV-GFP containing the
reporter gene GFP downstream of HCV IRES, was translated
in vitro in rabbit reticulocyte lysate using [35S]methionine in
the absence or presence of increasing concentrations of
LaR2C (20 M, 40 M, and 60 M). The cap-independent
initiation of translation occurring internally from HCV IRES
resulted in the synthesis of GFP. The translated GFP was
analyzed by electrophoresis followed by phosphorimaging
analysis, and the band intensities were quantitated by densi-
tometry. It was observed that the addition of the peptide
LaR2C led to a significant decrease in the HCV IRES activity
(80 to 95%) in a dosage-dependent manner, leading to reduced
synthesis of GFP (Fig. 5A, lanes 2 to 4). However, the addition
of similar concentrations of NSP to the translation reactions
did not show any significant effect (Fig. 5A, lanes 5 to 7). Also,
the peptide LaR2C didn’t affect the translation when capped
GFP RNA was used (Fig. 5B, lanes 2 to 4), indicating the
specificity of the peptide to selectively inhibit HCV IRES-
mediated translation. Furthermore, the addition of similar
concentrations of LaR2C peptide didn’t show inhibition of
hepatitis A virus (HAV) IRES (Fig. 5C). However, the addi-
tion of increasing concentrations (20 M, 40 M, and 60 M)
of LaR2C peptide showed only up to 44 to 49% inhibition of
the PV IRES-mediated translation of the reporter gene firefly
luciferase. The results suggest that the LaR2C peptide might
be more effective in inhibiting HCV IRES compared to other
IRES function.
LaR2C inhibits HCV IRES-mediated translation in vivo. As
we have observed that LaR2C showed a dominant negative
effect on HCV IRES-mediated translation in vitro, we wanted
to investigate whether the same peptide can inhibit the HCV
IRES-mediated translation in vivo as well. As a first step,
sequence coding for the peptide LaR2C was cloned into bac-
FIG. 5. Effect of LaR2C on HCV IRES-mediated translation in vitro. (A) One microgram of uncapped HCV IRES-GFP RNA was translated
in RRL in the absence (lane 1) or presence of increasing concentrations (20, 40, and 60 M) of either LaR2C (lanes 2 to 4) or NSP (lanes 5 to
7). The translation of GFP was analyzed on an SDS–12.5% polyacrylamide gel followed by phosphorimaging. The band corresponding to GFP is
indicated to the right of the panel. (B) One microgram of capped GFP RNA was translated in RRL in the absence (lane 1) or presence of
increasing concentrations (20, 40, and 60 M) of LaR2C (lanes 2 to 4). The translation of GFP was analyzed on an SDS–12.5% polyacrylamide
gel followed by phosphorimaging. The band corresponding to GFP is indicated to the right of the panel. (C and D) Two micrograms of either
capped HAV-bicistronic RNA (containing FLuc-HAV-GFP in order) or PV bicistronic RNA (containing RLuc-PV-FLuc in order) was translated
in the absence (lane 1) and presence of increasing concentrations (20, 40, and 60 M) of LaR2C (lanes 2 to 4). The translation of the reporter
genes was analyzed on an SDS–12.5% polyacrylamide gel followed by phosphorimaging. The bands corresponding to GFP (representing HAV
IRES function [C]) and FLuc (representing PV-IRES function [D]) are shown in the picture for clarity only. The intensities of the GFP band and
the FLuc band in each lane were quantitated using densitometry and represented in numbers below the respective lanes.
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terial expression vector pTAT, which would produce the pep-
tide as a fusion of HIV TAT peptide that has the property to
internalize into mammalian cells when supplied exogenously
into the medium (5) (Fig. 6A). Additionally, the presence of a
His tag in the fusion protein enabled the overexpressed TAT
fusion protein in E. coli BL21 cells to be purified by using
Ni-NTA affinity chromatography. Huh7 monolayer cells were
first transfected with the pcDNA3-HCV bicistronic construct,
and the transfectants were selected and maintained in medium
containing neomycin. These selected cells, which constitutively
express both reporter genes FLuc and RLuc from the HCV
bicistronic construct (Fig. 6B), were washed and layered with
medium containing 100 nM of TAT-LaR2C fusion protein and
incubated for 10 min. Similarly, as a negative control, another
set of dishes was layered with TAT-HA protein. After incuba-
tion, the cells were washed and incubated with fresh medium
and then harvested at different time intervals, 10 min, 6 h, and
12 h. The cells were then lysed, and FLuc and RLuc reporter
activities were measured. The relative luciferase activities were
represented as a ratio of FLuc to RLuc for normalization. The
results indicated that the cells layered with TAT-LaR2C
showed a decrease in the HCV IRES-mediated translation
over the control cells, while the TAT-HA did not have any
effect on HCV IRES-mediated translation (Fig. 6B). At 6 h
posttransfection, the inhibitory effect was pronounced (inhibi-
tion up to 60%), while the inhibitory effect was found to be
gradually decreasing upon prolonged incubation (12-h time
point), possibly due to degradation of TAT-LaR2C within the
cells. The presence of the His-tagged TAT-LaR2C protein
transduced into the cells was monitored by immunoblotting of
the cell extracts using anti-His antibody. The results showed a
dosage-dependent increase in the presence of TAT-LaR2C
protein inside the cells upon addition of increasing concentra-
tions of the fusion protein into the medium (data not shown).
Taken together, these results indicated that LaR2C does com-
pete with the interaction of cellular La protein with HCV
IRES RNA and exerts a dominant negative effect to inhibit
HCV IRES-mediated translation.
LaR2C peptide prevents the assembly of ribosomal com-
plexes on the HCV IRES. Previously, we demonstrated that
full-length La protein binding at the SL IV region triggers a
conformational change that facilitates ribosome assembly at
the HCV IRES RNA. Since the LaR2C peptide successfully
competes with the full-length La protein for binding with the
HCV IRES, we have investigated the effect of ribosome as-
sembly upon the addition of the LaR2C peptide in the reac-
tion. For this purpose, sucrose gradient centrifugation experi-
ments were performed, followed by the analysis of 48S and 80S
ribosomal peaks. 32P-labeled HCV IRES RNA was incubated
in translation reactions containing RRL and an amino acid
mixture and loaded onto a 5 to 30% sucrose gradient and
ultracentrifuged for 3 h at 30,000 rpm. The fractions were
collected from the bottom of the tube, and scintillation counts
were measured. The percentage of counts in each fraction was
plotted against the fraction volume of the gradient. When
wild-type HCV IRES RNA was used, two peaks were observed
in equilibrium, corresponding to 80S and 48S ribosomes asso-
ciated with the labeled HCV RNA (Fig. 7A). Upon addition of
20 M of the LaR2C peptide, the peaks corresponding to 80S
and 48S ribosomes were found to be reduced to some extent
(compare Fig. 7A and B). At a higher concentration (40 M)
of LaR2C, the 80S peak was found to be completely abolished,
and even the 48S peak was further reduced compared to the
control (compare Fig. 7C and A). However, the addition of a
40 M concentration of the NSP didn’t show significant alter-
ations in either of the 48S or 80S peaks in the ribosomal
assembly experiment (Fig. 7D). Interestingly, upon addition of
a further high concentration (60 M) of LaR2C peptide, even
the 48S peak was found to be drastically reduced along with the
80S peak (data not shown).
It has been demonstrated that in the case of HCV IRES
RNA, the 40S ribosomal subunit can form a stable binary
complex which is distinct from the 48S preinitiation complex
FIG. 6. Effect of TAT-LaR2C fusion protein on HCV IRES-medi-
ated translation in vivo. (A) Schematic representation of the TAT-
LaR2C fusion protein. The amino acid sequences of TAT and LaR2C
are highlighted. (B) Huh7 monolayer cells expressing HCV bicistronic
RNA were overlaid with 100 nM of either HA-TAT or TAT-LaR2C
fusion protein for 10 min. The cells were then harvested after different
time points (10 min, 6 h, and 12 h) and lysed, and the RLuc and FLuc
levels were measured using a Dual Luciferase assay system. The rela-
tive ratio of FLuc to RLuc was plotted at each time point. Black bars
represent control cells, white bars represent cells overlaid with HA-
TAT, and gray bars represent cells treated with TAT-LaR2C fusion
protein. The HCV bicistronic construct used in the cell line is indicated
on top of panel B. Data from the transfection experiments are ex-
pressed as means  standard deviations of three independent repli-
cates. (C) Absolute levels of RLuc and FLuc activities (in relative light
units) of a representative experiment are presented in the table.
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FIG. 7. Effect of LaR2C peptide on ribosomal assembly on the HCV IRES RNA. Sucrose gradient sedimentation profiles of 32P-labeled HCV
IRES RNA in the absence (A) or presence of increasing concentrations of the LaR2C peptide (B and C) or the NSP (D) after incubation in RRL
and separated on a 5 to 30% sucrose gradient are shown. The fractions (200 l) were manually collected from the bottom of the tube, and
scintillation counts were measured. The counts per minute of each fraction were shown as the percentage of the total counts added to the reaction
(	2  105 cpm) and were plotted against the volume of the gradient solution (0 to 8 ml). The ribosomal peaks corresponding to 48S and 80S are
indicated. Panel E represents the sedimentation profile of HCV IRES RNA incubated in RRL in the presence of 10 mM GMP-PNP alone, and
panel F is that obtained in the presence of both LaR2C (40 M) and GMP-PNP (10 mM).
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(26). However, this binary complex might not be separable
from the true 48S peak in the sucrose gradient centrifugation.
The actual 48S preinitiation complex would be competent for
the 60S joining, whereas the binary complex would not lead to
functional initiation complex formation. To further clarify
whether the inhibition at the 80S complex formation by the
LaR2C peptide was due to its effect at the preinitiation com-
plex formation, we have performed the ribosome assembly
reaction in the presence of 10 mM GMP-PNP. GMP-PNP,
which is a nonhydrolyzable analog of GTP, inhibits translation
initiation at the 48S stage by preventing the release of eIF2. As
expected, the addition of GMP-PNP abolished the 80S peak
and caused the accumulation of 48S ribosome preinitiation
complexes in the control reaction (Fig. 7E). Interestingly, when
LaR2C peptide (40 M) was added to the reaction (in the
presence of 10 mM GMP-PNP), in addition to a drastic de-
crease in the 80S peak, a significant decrease in the 48S peak
was also observed (compare Fig. 7A, E, and F). The results
suggest that LaR2C peptide might interfere with the transition
step between the HCV-40S binary complex to the 48S complex,
resulting in the formation of defective complex that is incom-
petent for 60S joining. Since the addition of LaR2C didn’t
show accumulation of the 48S peak (as observed in the case of
GMP-PNP), and rather decreases the 48S peak at higher con-
centrations, it seems that the complex might be dissociating
eventually.
The result clearly reconfirms the role of La protein in the
formation of a functional 48S ribosome complex on HCV
IRES, as suggested by our earlier work (28, 29) and also a
recent report (11).
Taken together, the results strongly suggest that the LaR2C
peptide acts as a dominant negative and might compete for the
binding of La protein to the SL IV region of the HCV IRES;
as a consequence, the formation of a functional ribosomal
initiation complex is severely affected, resulting in the inhibi-
tion of HCV IRES-mediated translation.
DISCUSSION
A recent report proposed a revised model depicting a se-
quential pathway of HCV IRES-mediated translation which is
distinct from canonical initiation of cellular mRNAs. Accord-
ing to this model, HCV IRES begins translation as an IRES-
40S complex that is followed by formation of a 48S interme-
diate prior to GTP hydrolysis and 60S joining to assemble the
80S complex. The model also suggests additional function dur-
ing translation initiation, which requires maintenance of the
HCV IRES structure (26). Although the 48S assembly with
HCV IRES-40S is known to require only eIF3 and ternary
complex eIF2-GTP-Met-tRNAi (21), trans-acting factors like
La protein, polypyrimidine tract-binding protein, etc., which
have been shown to stimulate IRES activity, might help in
stabilizing the initiation complex. Previous reports from our
laboratory showed that La binding to SL IV of HCV IRES
RNA through RRM2 might induce conformational alterations
within the RNA which facilitate internal initiation (29). We
have shown that La protein binding (through RRM2) at the
GCAC, near iAUG, apparently has a double effect, and first, it
indirectly facilitates the S5 interaction with the HCV IRES and
thus helps in 48S assembly. Second, the RRM2 binding at the
SL IV region induces conformational alteration required for
functional initiation complex formation. Thus, the mutant
HCV IRES RNA, where GCAC sequences were altered, failed
to bind La-RRM2 and thus prevented the S5 interaction as
well as affected the conformational alteration leading to trap-
ping of the ribosomes at the 80S complex, resulting in inhibi-
tion of IRES activity. However, LaR2C retained the ability to
bind to HCV IRES, but it might not be capable of other
essential functions performed by full-length La protein in stim-
ulating HCV IRES function. This might explain the dominant
negative activity shown by LaR2C on HCV IRES-mediated
translation both in vitro and in vivo.
Interestingly, a recent report demonstrated that a dominant
negative La mutant, where amino acids 226 to 348 (encom-
passing part of RRM3) had been deleted, inhibits the initiation
of formation of the 48S ribosome complex and proposed a
possible role for the La protein in the formation of functional
initiation complex (11). Since the mutant La lacked the RRM3
but retained the RRM2, it might still be able to establish
partial contact with the SL IV region near the iAUG. Our
preliminary studies showed that RRM3 interacts with the SL
III region, which largely encompasses the 40S contact points
(reference 24 and data not shown). Thus, the La mutant lack-
ing RRM3 is expected to have a drastic effect on 48S complex
formation and the consequent decrease in 80S functional com-
plex formation.
This study suggests that LaR2C peptide prevents full-length
La protein binding to the HCV SL IV, thereby preventing the
conformational alterations required for the functional initia-
tion complex formation. In all the three approaches, the result
reinforces the role of La protein in ribosome assembly during
HCV IRES-mediated translation.
Studies from different laboratories suggest that the La pro-
tein binds to various RNAs using different combinations of
RRMs. Although RRM1 (sometimes referred to as the “La
motif”) does not bind RNA on its own, it contributes signifi-
cantly to the recognition of UUU-OH-containing RNAs (25).
Also, it has been demonstrated previously that deletion of the
N-terminal residues of RRM1 decreased the affinity for bind-
ing to HIV leader RNA as well as HCV IRES RNA (9, 23).
While the N-terminal region of the La protein has been shown
to be an interacting domain with poliovirus RNA (35), in the
case of HCV, both the N-terminal (containing RRM1 and
RRM2) and C-terminal (containing RRM3 and the hydropho-
bic domain) regions of the La protein have been shown to be
capable of binding independently to the HCV IRES and stim-
ulate translation to some extent (3, 28). Interestingly, the
RRM2-derived peptide LaR2C didn’t inhibit PV IRES-medi-
ated translation as efficiently as observed in case of HCV
IRES, suggesting that La-RRM2 may not be as essential in PV
IRES function. Although there is no report on the requirement
of La protein in HAV IRES-mediated translation, it is possible
that even if it interacts with HAV IRES, it might not interact
through RRM2. Thus, as expected, the LaR2C peptide didn’t
show an inhibitory effect on HAV IRES-mediated translation.
From our studies, it appears that the role of La-RRM2 in
ribosome assembly could be more effective for the hepatitis C
virus IRES-mediated translation.
Interestingly, it appeared from the competition UV cross-
linking experiment that in addition to La protein, the peptide
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LaR2C might have altered the binding of some other cellular
protein factors to the HCV IRES RNA. Since La protein also
binds to the SL III region of HCV IRES (data not shown),
where the majority of the eIF3 subunits have been reported to
interact (8), it is tempting to speculate that the competition of
full-length La protein binding by the LaR2C peptide might
indirectly affect the interaction of eIF3 subunits. In fact, bands
corresponding to some cellular protein binding showed more
intensity upon addition of the LaR2C peptide, which could be
due to the increasing availability of the binding sites on the
HCV IRES RNA that were otherwise occupied by full-length
La protein binding. Alternatively, the peptide might sequester
some other protein factors giving better access to these cellular
proteins to bind more strongly to the HCV IRES RNA. Thus,
the effect of the peptide on HCV IRES-mediated translation
could be a combination of such effects.
La protein binding through other domains (RRMs and the
hydrophobic region) is not expected to be affected due to the
RRM2-derived peptide binding at the HCV IRES. Thus, at
lower concentrations of LaR2C peptide (20 and 40 M), the
competition UV cross-linking results demonstrated only a 40%
decrease in La binding. However, at a higher concentration (60
M), a significant reduction of La binding with the HCV IRES
was observed. It is possible that at higher concentrations, the
peptide LaR2C might sequester cellular La protein and also
interfere with its binding to other binding sites within HCV
IRES, resulting in a much more pronounced effect. In fact, a
previous report did suggest that a peptide derived from RRM1
of the La protein might bind full-length La protein and seques-
ter its binding with the HCV IRES RNA to inhibit internal
initiation of translation (23).
The TAT-LaR2C fusion protein was capable of inhibiting,
but not total abrogation of, HCV IRES-mediated translation
of FLuc activity in vivo. This might be due to the fact that the
TAT-LaR2C might not bind HCV IRES in vivo with similar
affinity as the LaR2C peptide. Alternatively, the HCV IRES
requires very low concentrations of La protein for its activity,
and TAT-LaR2C protein was not able to compete out the
binding of La protein totally in Huh7 cells. But considering the
half-life of both luciferase activities, it appears that the 60%
decrease in FLuc activity at the 6-h time point actually reflects
the residual luciferase activity. Since the RLuc activity didn’t
change during this time period, it is possible that the Tat-
LaR2C protein might have selectively blocked the HCV IRES
function, resulting in a drastic reduction in new synthesis of
FLuc protein. However, the specificity and efficacy of the pep-
tide to act as a dominant negative could possibly be further
enhanced if the size of the peptide could be shortened after
further characterizing and delineating the RNA-binding do-
main within LaR2C. Alternatively, the LaR2C peptide se-
quence could be delivered in vivo by using lentiviral vectors
under an inducible promoter to test the selective inhibitory
activity. This would then be useful to develop an effective
inhibitor of HCV IRES translation.
Several strategies have been used to target essential RNA-
protein interactions to block the HCV IRES-mediated trans-
lation. Antisense oligonucleotides targeted to domain IIId of
HCV IRES have been used to compete with 40S ribosomal
subunit binding and prevent in vitro translation (36). Reports
from our laboratory have shown that a small RNA molecule
(SLIIIef) corresponding to the subdomain ef within stem-
loop III of the HCV IRES RNA, when introduced in trans, can
bind to the cellular proteins and antagonize their binding to
the viral IRES, thereby inhibiting HCV IRES-mediated trans-
lation (30). It would be interesting to investigate whether
SLIIIef RNA and LaR2C peptide could be used in combi-
nation to prevent the ribosome assembly to block HCV RNA
translation more effectively. Recently, it has been shown that a
peptide corresponding to 11 to 28 amino acids of La protein is
capable of inhibiting both poliovirus and HCV IRES-mediated
translation (23). Although the mode of action of this peptide is
yet to be elucidated, it appeared that La peptide lacks the
HCV RNA binding ability. In this study, we have identified the
peptide LaR2C, which retains the RNA binding ability and
also inhibits HCV IRES-mediated translation specifically with-
out having a significant effect on cap-dependent translation.
Due to its potential dominant negative effect, it would also be
interesting to investigate the efficacy of the peptides in combi-
nation to develop an effective antiviral strategy against hepa-
titis C virus infection.
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